1.13
-0.39(-25.66%)
Currency In USD
| Previous Close | 1.52 |
| Open | 1.35 |
| Day High | 1.42 |
| Day Low | 0.92 |
| 52-Week High | 7.69 |
| 52-Week Low | 0.91 |
| Volume | 4.13M |
| Average Volume | 5.59M |
| Market Cap | 3.34M |
| PE | -0.09 |
| EPS | -12.69 |
| Moving Average 50 Days | 1.31 |
| Moving Average 200 Days | 3.04 |
| Change | -0.39 |
If you invested $1000 in Pasithea Therapeutics Corp. (KTTA) since IPO date, it would be worth $15.87 as of May 08, 2025 at a share price of $1.13. Whereas If you bought $1000 worth of Pasithea Therapeutics Corp. (KTTA) shares 3 years ago, it would be worth $56.5 as of May 08, 2025 at a share price of $1.13.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Pasithea Therapeutics Announces Closing of $5 Million Public Offering
GlobeNewswire Inc.
7 hours ago
Additional Gross Proceeds of Approximately $1.3 Million Received Upon Exercise of Certain Warrants Issued in the Public OfferingMIAMI, May 07, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics, Corp. (“Pasithea,” or the “Company”) (Nasdaq: KTTA; KTTAW
Pasithea Therapeutics Announces Pricing of $5 Million Public Offering
GlobeNewswire Inc.
May 06, 2025 3:10 PM GMT
MIAMI, May 06, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics, Corp. (“Pasithea,” or the “Company”) (Nasdaq: KTTA; KTTAW), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of
Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004
GlobeNewswire Inc.
May 06, 2025 11:03 AM GMT
-- PAS-004 shows up to 91% inhibition of pERK, confirming substantial target engagement -- -- One patient in cohort 4A with stage 4 KRAS G12R mutated pancreatic cancer achieves over 5 months of stable disease with tumor volume reduction of -9.8% -- M